LUNGHI, Barbara
 Distribuzione geografica
Continente #
NA - Nord America 5.051
EU - Europa 1.373
AS - Asia 1.249
SA - Sud America 82
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 3
Totale 7.765
Nazione #
US - Stati Uniti d'America 5.022
SG - Singapore 537
CN - Cina 438
UA - Ucraina 319
IT - Italia 281
DE - Germania 250
TR - Turchia 166
GB - Regno Unito 151
SE - Svezia 75
FI - Finlandia 74
BR - Brasile 71
PL - Polonia 68
ID - Indonesia 35
BE - Belgio 34
NL - Olanda 32
CA - Canada 26
HK - Hong Kong 23
FR - Francia 20
CZ - Repubblica Ceca 16
VN - Vietnam 12
AT - Austria 9
GR - Grecia 8
IN - India 8
IR - Iran 7
LT - Lituania 7
CH - Svizzera 5
BD - Bangladesh 4
JP - Giappone 4
PT - Portogallo 4
RO - Romania 4
RU - Federazione Russa 4
TW - Taiwan 4
AU - Australia 3
IQ - Iraq 3
AL - Albania 2
AR - Argentina 2
BY - Bielorussia 2
CO - Colombia 2
ES - Italia 2
EU - Europa 2
IE - Irlanda 2
JO - Giordania 2
MX - Messico 2
PY - Paraguay 2
VE - Venezuela 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AO - Angola 1
BG - Bulgaria 1
CI - Costa d'Avorio 1
CL - Cile 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
EC - Ecuador 1
KR - Corea 1
LB - Libano 1
MA - Marocco 1
MK - Macedonia 1
OM - Oman 1
PK - Pakistan 1
RS - Serbia 1
TH - Thailandia 1
TN - Tunisia 1
UY - Uruguay 1
UZ - Uzbekistan 1
Totale 7.765
Città #
Woodbridge 595
Fairfield 594
Houston 381
Chandler 369
Jacksonville 344
Santa Clara 300
Ashburn 275
Singapore 253
Seattle 252
Ann Arbor 239
Wilmington 210
Cambridge 194
New York 169
Izmir 102
Ferrara 98
Nanjing 98
Boardman 93
Princeton 84
Beijing 74
Warsaw 68
San Diego 57
Milan 44
Dearborn 37
Shanghai 37
Shenyang 36
Jakarta 34
Brussels 33
Bremen 31
Munich 25
Hebei 24
Hong Kong 23
Jiaxing 20
Tianjin 20
Nanchang 19
Redwood City 18
Changsha 16
London 16
Los Angeles 15
Brno 13
Kunming 13
Mountain View 13
Auburn Hills 12
Des Moines 12
Düsseldorf 12
Mcallen 12
Norwalk 12
Rome 12
Dong Ket 11
Helsinki 11
Nuremberg 11
Falkenstein 9
Redmond 9
Hangzhou 8
Jinan 8
Montréal 8
Ottawa 8
San Mateo 8
Toronto 8
Vienna 7
Abdullah 6
Chicago 6
Florence 6
Frankfurt am Main 6
Zhengzhou 6
Bologna 5
Falls Church 5
Monmouth Junction 5
Orange 5
Verona 5
Castelcovati 4
Fuzhou 4
Hefei 4
Ningbo 4
Padova 4
Sala 4
Shenzhen 4
Athens 3
Augusta 3
Guangzhou 3
Hyderabad 3
Lusia 3
Mülheim-kärlich 3
Reggio Nell'emilia 3
São Paulo 3
Tappahannock 3
Washington 3
Wuhan 3
Addison 2
Albignasego 2
Alvorada 2
Atlanta 2
Catania 2
Changchun 2
Dhaka 2
Dronten 2
Ferrara di Monte Baldo 2
Fortaleza 2
Genoa 2
Genova 2
Guarulhos 2
Totale 5.656
Nome #
C6orf10 low-frequency and rare variants in italian multiple sclerosis patients 212
Activated factor VII-antithrombin complex predicts mortality in patients with stable coronary artery disease: a cohort study 178
Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family 173
An integrated genomic-transcriptomic approach supports a role for the proto-oncogene BCL3 in atherosclerosis 165
Factor XI rs2036914 gene polymorphism and occurrence of adverse events after percutaneous coronary intervention. A prospective evaluation. 160
Polymorphisms at LDLR locus may be associated with coronary artery disease through modulation of coagulation factor VIII activity and independently from lipid profile 153
VITAMIN K-INDUCED MODIFICATION OF COAGULATION PHENOTYPE IN VKORC1 HOMOZYGOUS DEFICIENCY 152
Changes in expression profiles of internal jugular vein wall and plasma protein levels in multiple sclerosis 151
A highly polymorphic microsatellite in the factor V gene is an informative tool for the study of factor V-related disorders 148
Genetic determinants of activated factor VII antithrombin complex plasma concentration include tissue factor, factor VII and endothelial protein C receptor gene variants 146
A novel mutation (Leu817Pro) causing type 2A von Willebrand disease. 137
A heparin cofactor II mutation (HCII Rimini) combined with factor V Leiden or type I protein C deficiency in two unrelated thrombophilic subjects 132
The F11 rs2289252 polymorphism is associated with FXI activity levels and APTT ratio in women with thrombosis 130
Asymptomatic carriership of factor V Leiden and genotypes of the fibrinogen gene cluster 126
A factor V genetic component differing from factor V R506Q contributes to the activated protein C resistance phenotype 124
FV multiallelic marker detects genetic components of APC resistance contributing to venous thromboembolism in FV Leiden carriers 120
Mutation pattern in clinically asymptomatic coagulation factor VII deficiency 120
Molecular bases of CRM+ factor X deficiency: a frequent mutation (Ser334Pro) in the catalytic domain and a substitution (Glul02Lys) in the second EGF‐like domain 117
An underestimated combination of opposites resulting in enhanced thrombotic tendency 117
Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia 117
A new factor V gene polymorphism (His 1254 Arg) present in subjects of African origin mimics the R2 polymorphism (His 1299 Arg) 115
Mutations in the R2 FV gene affect the ratio between the two FV isoforms in plasma 112
The factor VIII D I24I E polymorphism is associated with decreased factor VIII activity and not with activated protein C resistance levels 111
New coagulation factor V gene polymorphisms define a single and infrequent haplotype underlying the factor V leiden mutation in Mediterranean populations and Indians 111
A novel factor V null mutation detected in a thrombophilic patient with pseudo-homozygous APC resistance and in an asymptomatic unrelated subject 110
The factor V Glu1608Lys mutation is recurrent in familial thrombophilia 109
Performance prediction models based on anthropometric, genetic and psychological traits of Croatian sprinters 108
Resistance to activated protein C, associated with oral contraceptives use; effect of formulations, duration of assumption, and doses of oestro- progestins 107
A missense mutation (Y1702C) in the coagulation factor V gene is a frequent cause of factor V deficiency in the Italian population. 106
Risks factors for highly unstable response to oral anticoagulation: a case-control study 105
Modulation of factor V levels in plasma by polymorphisms in the C2 domain 105
Apolipoprotein C-III Strongly Correlates with Activated Factor VII-Anti-Thrombin Complex: An Additional Link between Plasma Lipids and Coagulation 105
Expression profiles of the internal jugular and saphenous veins: Focus on hemostasis genes 105
Venous thromboembolism in young women - Role of thrombophilic mutations and oral contraceptive use 104
Increased factor VIII coagulant activity levels in male carriers of the factor V R2 polymorphism 104
Does factor V Asp79His (409 G/C) polymorphism influence factor V and APC resistance levels? 103
Novel phenotype and gamma-glutamyl carboxylase mutations in combined deficiency of vitamin K-dependent coagulation factors 103
Phenotypic homozygous activated protein C resistance associated with compound heterozygosity for Arg506Gln (factor V Leiden) and His1299 Arg substitutions in factor V 102
Interaction of occupational posture, lifestyle and genetic components of thrombophilia 101
Resistance to activated protein C in healthy women taking oral contraceptives 100
Molecular basis of coagulation factor V deficiency caused by the R1698W inter-domain mutation. 97
Detection of new polymorphic markers in the factor V gene: Association with factor V levels in plasma 96
Expression of the normal factor V allele modulates the APC resistance phenotype in heterozygous carriers of the factor V Leiden mutation. 96
null 95
Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes 93
An Italian Family with a Novel Mutation Causing Type 2A von Willebrand Disease and with Reduced Levels of von Willebrand Factor not Linked with the von Willebrand Factor Gene. 93
Factor V gene mutations (R2 gene) are associated with coronary artery disease inelderly people 89
null 88
Phenotype and genotype expression in pseudohomozygous factor V-LEIDEN - The need for phenotype analysis 87
Molecular bases of pseudo-homozygous APC resistance: The compound heterozygosity for FV R506Q and a FV null mutation results in the exclusive presence of FV Leiden molecules in plasma 86
Increased Susceptibility to Proteases in Type 2A von Willebrand Disease Associated with two Novel Mutations (Val 867 Glu, Pro 864 His). 86
Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention: Relationship with gene polymorphisms and clinical outcome 84
Factor V markers for the detection of genetic components of APC resistance in venous thrombosis 80
Factor V Levels in a Cohort of Patients Eligible for Oral Anticoagulant Therapy. 79
Factor V markers for the detection of genetic components of APC resi stance in venous thrombosis. 77
Severe bleeding and absent ADP-induced platelet aggregation associated with inherited combined CalDAG-GEFI and P2Y12 deficiencies 77
CMR+ Factor V deficiency Arg2080Cys: A model to investigate altered C2 domain-membrane interaction. 76
Polimorfismi funzionali e terapia anticoagulante 71
Functional genetics 71
Contribution of low density lipoprotein receptor-related protein genotypes to coagulation factor VIII levels in thrombotic women 69
Functional polymorphisms in the LDLR and pharmacokinetics of Factor VIII concentrates 66
Hemostasis gene expression of the internal jugular and saphenous veins 64
null 63
Studio di Mutazioni in Geni dell'Emostasi. 60
Evaluation of FV mRNA to define the residual FV expression levels in severe FV deficiency 60
The Asialoglycoprotein Receptor Minor Subunit Gene Contributes to Pharmacokinetics of Factor VIII Concentrates in Hemophilia A 60
Expression and characterization of a factor V mutation (E1608K) detected in familial thrombophilia. 59
The asymptomatic carriership of thrombophilic defects is associated with frequent genotypes of the fibrinogen gene cluster. 59
Contribution of asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms to full-length FVIII concentrate pharmacokinetics 58
Cis-segregation of c.1171c>t stop codon (p.r391*) in serpinc1 gene and c.1691g>a transition (p.r506q) in f5 gene and selected gwas multilocus approach in inherited thrombophilia 56
Studio di mutazioni in geni dell’emostasi. 54
F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes 53
Lesioni molecolari ricorrenti sono responsabili di difetti funzionali del fattore VII. 50
Detection of New Polymorphic Markers in the Factor V Gene. 50
The asialoglycoprotein receptor ASGR2 5’ UTR polymorphisms influence several parameters of full-length FVIII concentrate pharmacokinetics 50
Aptamer-modified FXa generation assays to investigate hypercoagulability in plasma from patients with ischemic heart disease 44
In vivo modulation of a dominant-negative variant in mouse models of von Willebrand disease type 2A 44
Combination of Genomic and Transcriptomic Approaches Highlights Vascular and Circadian Clock Components in Multiple Sclerosis 39
Combination of CLEC4M rs868875 G-Carriership and ABO O Genotypes May Predict Faster Decay of FVIII Infused in Hemophilia A Patients 38
The p.P1127S pathogenic variant lowers von Willebrand factor levels through higher affinity for the macrophagic scavenger receptor LRP1: Clinical phenotype and pathogenic mechanisms 29
Whole-Exome Sequencing in a Family with an Unexplained Tendency for Venous Thromboembolism: Multicomponent Prediction of Low-Frequency Variant Deleteriousness and of Individual Protein Interaction 26
Influence of low-density lipoprotein (LDL) receptor-related protein and ABO blood group genotypes on factor XI levels. 26
Modulation of factor VIII pharmacokinetics by genetic components in factor VIII receptors 23
Factor V Kuwait alias factor V R3: A rare polymorphism of uncertain functional significance 21
Association of membranous nephropathy with familial resistance to activated protein C 18
In vitro and ex vivo rescue of a nonsense mutation responsible for severe coagulation factor V deficiency 17
Genetic components in factor VIII receptors for individual and genotype-modeled hemophilia A treatment 12
Reduced inhibition of activated prothrombin by heparin and venous thromboembolism: heparin resistance revisited 6
Totale 7.899
Categoria #
all - tutte 41.918
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.918


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020251 0 0 0 0 0 0 0 0 0 154 58 39
2020/20211.119 110 101 76 118 38 100 91 116 41 138 134 56
2021/2022903 96 87 47 71 50 18 54 47 21 59 83 270
2022/2023902 93 78 24 109 130 130 67 76 100 15 46 34
2023/2024563 34 39 18 20 36 183 9 26 17 7 13 161
2024/20251.243 44 31 172 66 243 169 46 77 316 79 0 0
Totale 7.899